Adaptive Biotechnologies GAAP EPS of $0.02 beats by $0.11

Adaptive Biotechnologies (ADPT) reported Q3 GAAP EPS of $0.02, exceeding estimates by $0.11, with revenue of $83.9M, beating by $12.3M. The company raised its full-year revenue guidance for the MRD business to $276M-$286M, up from $268M previously.

Original reporting
Published Nov 4, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ADPT
Bullish
high confidence
Mentioned
$ADPT
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ADPTBullishMed
01

Why it matters

The earnings surprise provides a short‑term catalyst for price appreciation, though long‑term performance hinges on pipeline progress.

02

Market read

Earnings beat offers a timely trading opportunity for ADPT, with potential spillover to the broader biotech sector.

03

What to watch

Guidance for the MRD business remains modest; future growth may be constrained.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Adaptive Biotechnologies (ADPT) is a US‑listed biotech focused on immune profiling and diagnostics.

Company-level read

Ticker impact

$ADPTBullishHigh confidence
Context

Adaptive Biotechnologies reported Q3 GAAP EPS of $0.02, beating expectations by $0.11 and revenue of $83.9M, beating by $12.3M.

Expected impact

likely upward as the market prices in the earnings beat

Evidence & confidence

Both EPS and revenue exceeded consensus, a rare positive surprise for a small‑cap biotech, prompting short‑covering and buying.

Market effects

Positive earnings may lift other biotech peers as investors rotate into the sector.

Limited to US biotech market; no broader regional effect.

Minimal global impact beyond biotech investors.

Counterpoint

The beat may be priced in quickly, and the stock could face profit‑taking.

Key entities

  • Adaptive Biotechnologies

    Biotech firm reporting Q3 earnings.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.

$ADPTHighAI 8/10

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet